S&P 500 closes at another record high
Seana Smith
The S&P 500 eeks out a new record close amid a wave of earnings. Investors also weighing the latest trade developments. Here with more on the trading day takeaways is Yahoo Finance's Jared Blikre. Jared.
00:11
Jared Blikre
Well, thank you. We got to talk about some breakouts today and uh, specifically in some sectors. I'm also going to show you some industries. I like this because the markets are kind of quiet overall. We're very much in a bull market mode, which means low volatility, low volume for the most part. But here are some sectors that caught my eye today. First, utilities. I've been talking about this for a few days. Now let me put a year-to-date candlestick chart on here so we can see the breakout. And here we go. These last three days have been to record highs. Utilities doesn't really catch a lot of headlines, although within the last year, we did see them come become part of the AI trade. And so we saw them generate some headlines there. But there's utilities. These are three record highs in a row there. Also, real estate. Uh, we also, I don't talk about this one a lot. Not at record highs, but kind of broke out of this base here. And it's just kind of emblematic of a bull market where you have sectors kind of take a backseat while others reassert. And that's what we've seen because tech, which has been leading this bull market since October of 22, uh, 2022, it took a backseat today. It was the only sector that closed in the red. So real estate is another one. And then consumer discretionary. And this is a little bit more flashy because we got Amazon in there, we got Tesla. And here we can see a little bit of an uptrend, but this was the highest since we've seen all the way back to March or so in there, February, March. And I wouldn't be surprised if we knocked on those record highs pretty quickly, but that depends on what Amazon and Tesla do. Um, we can also see this in some of our leaders. And this is, this board right here is just a collection of ETFs for the most part of markets I like to look at, and home builders. Home builders is a group I have not looked at in forever on this board right here, but you can see, uh, closing in. I don't know if those are the record highs down there. Let's put a one-year chart on. There we go. And so we're at the highest since earlier in the year and we've got some territory to reclaim here. But really interesting to see the home builders kind of perk up in this market, uh, and, you know, financials as well because we're, we are in the midst of earning season. Have we seen, uh, some of those spillover effects. Here's tan. This is a solar ETF. Highest since what? We're probably going back to last November and uh, that's the Invesco solar tan ETF and really interesting to see solar kind of reassert at times that are opposite the uh, traditional energy trade. And then, uh, cannabis. Now cannabis is not one of those headline sectors. This is, I'll show you a six-year chart and I'll show you why this has not been the greatest trade down 94%. Nevertheless, keeping with the theme of the day here, it did break to the upside. And so that's what I'm looking at here. And I think I got one more. Oh, I said consumer discretionary before. It's cousin is XRT. This is more traditional brick and mortar retail, but it also has some online stuff there, but more retail. You're not going to see, uh, the Amazon in this particular cohort, but nevertheless, look at that. If it's not the highest price in the year, it's touching it. So that's kind of the way, uh, the breakouts are shaking up today.
05:13
Seana Smith
Outside of stocks, Jared, where are we seeing strength?
05:16
Jared Blikre
Metals. All right, we got to talk some metals and commodities. This has been an evolving story. I've been talking about this. I've done several segments throughout the days of the last few weeks on the Metals Complex. And that is because commodities are typically a release valve when you have economic factors when the economy is kind of where it is where
05:38
Jared Blikre
the Fed is where it is right now. So let me just show you what gold has been doing today. By the way, gold, another record close. We haven't seen a record close in gold for some time. So here's year to date, and I'm going to show you the candlesticks there. It's been consolidating since April, finally broke to the upside today, just barely didn't get an intraday record, but we got a closing record. So gold futures definitely on my mind, 3,500. Well, we you break out of 3,500, you're going to see a lot potentially of upside just because of the length of this consolidation. Also, copper, things are getting more expensive to build with. This is another theme, and this is uh, you know, the run up to the global financial crisis, commodities were a huge deal because they were exploding to the upside. And it wasn't just stuff you build with, it was stuff you eat. And so food was in there too. But here's another record high for copper. And then silver, I'm going to show you a longer term chart here. Let's get the max chart. I'll put some lines on it. And this is the highest since about 2012 somewhere in there. So that's a 13 year high for silver. So things definitely breaking to the upside there as well.
07:06
Seana Smith
Should we do a quick check on crypto?
07:09
Jared Blikre
Yes, because I'm talk and dollars too. Stable coins backing dollars. I'm going to get back. I quoted uh, Dimitri Kous of the Hidden Forces Podcast yesterday. And um, we're going to listen to a clip of him. He was doing a stocks and translation interview. Yesterday we were talking about the decentralized nature of the US dollar. You heard that correctly. And today he's going to talk about stable coins. Let's take a listen.
07:35
Speaker A
That parallels the the the financialization of the US economy because it also be made, made it easier to generate outside financial returns more quickly. And we certainly have seen that. I think that um, one of the silver linings with respect to what's going on in crypto right now, despite again the trends of financialism I talked to in its origin point in crypto is what's going on with stable coins, because even though a lot of what's going on through the administration, the tariffs and, and not so much, not as much the tariffs, but more, I think, the uncertainty around policy making in this administration has been, I think, bearish for the dollar. I think that the um, the adoption of stable coins and the passing of legislation that is more amenable to their use cases is actually something that could be uh, positive for the dollar.
08:53
Jared Blikre
So stable coins providing another use case for the dollar. Just Kevin getting a little lift to the greenback.
09:01
Seana Smith
Covered a lot of ground. Anything we missed quickly.
09:04
Jared Blikre
Rates 30 year has dropped 10 basis points in the last two days. Love that. Want to continue to watch that tomorrow. The 30 year at 4.9%.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
6 minutes ago
- Yahoo
Hims & Hers Shares Plunge. Is This a Buying Opportunity or Should Investors Run for the Hills?
Key Points Hims & Hers Health continues to post robust growth. Shares sold off, however, after revenue missed analyst expectations. The stock is still reasonably valued given its growth prospects. 10 stocks we like better than Hims & Hers Health › Hims & Hers Health (NYSE: HIMS) is one of the most volatile stocks on the market at the moment, prone to big swings in either direction. This is true even intraday, as the stock plunged following the company's second-quarter results, only to rally back, only to plunge again. As of this writing, the stock is still trading up more than 130% this year. Let's take a closer look at the most recent earnings results for this telehealth company focused on providing accessible and affordable healthcare solutions for various health and wellness needs, and its prospects. Who knows, you might want to jump in on this somewhat volatile growth stock. Hims saw strong revenue growth in Q2 Hims & Hers continued to deliver outstanding revenue growth in Q2, with sales climbing 73% year over year to $544.8 million. That was toward the high end of its forecast for revenue of $530 million to $550 million, but it missed analyst expectations for revenue of $552 million. Monthly online revenue per subscriber jumped 30% to $74 per month, while the number of subscribers climbed 31% to nearly 2.44 million. The company said that the number of subscribers in both oral weight loss and dermatology grew more than 55% in the quarter. Customers using at least one personalized subscription increased by 89% to 1.5 million, representing more than 60% of the Hims & Hers subscriber base. It said that 70% of new patients who join the platform use a personalized treatment plan, and that the number of subscribers using a personalized treatment plan to treat multiple conditions skyrocketed 170% to more than 500,000. Revenue from GLP-1 weight loss drugs fell from $230 million in Q1 to $190 million in Q2, after Novo Nordisk ended a partnership with the telehealth company. Nonetheless, it still expects to generate $725 million of revenue this year from weight loss drugs, led by oral weight loss products and personalized doses. Hims & Hers continues to spend heavily on marketing to attract new customers. During the quarter, its marketing spending jumped 50% to nearly $218 million. Marketing expenses took up 40% of revenue in the quarter, though that was down from 46% a year ago, so the company continues to see leverage in this area despite the increased spending. Adjusted earnings before interest, taxes, depreciation, and amortization (EBITDA) surged to $82.2 million from $39.3 million a year ago. Adjusted earnings per share (EPS) came in at $0.17, topping the $0.15 analyst consensus as compiled by LSEG. Metric Q1 Results Growth (YOY) Revenue $544.8 million 73% Monthly online revenue per subscriber $74 30% Subscribers 2.44 million 31% Adjusted EBITDA $82.2 million 109% Adjusted EPS $0.17 183% Marketing expense $231 million 77% Marketing as % of revenue 40% (600 basis points) Gross margin 76% (500 basis points) Data source: Hims & Hers Health. YOY = year over year. Looking ahead, Hims & Hers maintained its forecast for 2025 revenue to be between $2.3 billion and $2.4 billion, equal to growth of 56% to 63%. It also kept its adjusted EBITDA guidance of $295 million to $335 million. For Q3, it projected revenue of between $570 million and $590 million, and adjusted EBITDA of $60 million to $70 million. The company is starting to look toward international expansion to bolster growth. It will begin by focusing on Canada next year, while its acquisition of Zava in July will help it expand into Europe. It also anticipates entering the Latin American and Asian markets in the coming years. Hims & Hers also continues to expand into new areas. It will launch hormonal health soon, starting with lab testing. The company believes this will help it reach its targets of $6.5 billion in revenue and $1.3 billion in adjusted EBITDA in 2030. Is the stock a buy? Hims & Hers continues to be a growth engine. Even though there's been some disruption from its spat with Novo Nordisk, it is still seeing strong growth across different health categories. With the company moving into new areas, like hormonal health and longevity, and looking to expand internationally, it has a lot of growth opportunities ahead. Meanwhile, with the majority of its subscribers on personalized treatment plans, it has a pretty sticky user base. From a valuation standpoint, the stock trades at a forward price-to-earnings (P/E) ratio of around 55 based on the analyst consensus for 2025. But its forward price/earnings-to-growth ratio (PEG) is under 0.6, and stocks with PEG ratios below 1 are usually considered undervalued. Given that it operates a subscription business with high gross margins, you can also look at the stock from a price-to-sales perspective; on that front, it trades at a multiple of 5.5 times 2025 analyst estimates. Overall, I'd say, based on the type of business the company is in, that it's still reasonably priced. However, it's still a volatile stock that carries some risk depending on what happens in the weight loss segment. Still, I really like its international opportunity, and think Hims & Hers Health could have solid long-term upside from here. Should you invest $1,000 in Hims & Hers Health right now? Before you buy stock in Hims & Hers Health, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Hims & Hers Health wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $653,427!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,119,863!* Now, it's worth noting Stock Advisor's total average return is 1,060% — a market-crushing outperformance compared to 182% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of August 4, 2025 Geoffrey Seiler has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Hims & Hers Health. The Motley Fool recommends Novo Nordisk. The Motley Fool has a disclosure policy. Hims & Hers Shares Plunge. Is This a Buying Opportunity or Should Investors Run for the Hills? was originally published by The Motley Fool 登入存取你的投資組合
Yahoo
6 minutes ago
- Yahoo
ArcelorMittal (AMS:MT) Strong Profits May Be Masking Some Underlying Issues
Explore ArcelorMittal's Fair Values from the Community and select yours The market shrugged off ArcelorMittal S.A.'s (AMS:MT) solid earnings report. We think that investors might be worried about some concerning underlying factors. Trump has pledged to "unleash" American oil and gas and these 15 US stocks have developments that are poised to benefit. How Do Unusual Items Influence Profit? For anyone who wants to understand ArcelorMittal's profit beyond the statutory numbers, it's important to note that during the last twelve months statutory profit gained from US$1.5b worth of unusual items. While it's always nice to have higher profit, a large contribution from unusual items sometimes dampens our enthusiasm. We ran the numbers on most publicly listed companies worldwide, and it's very common for unusual items to be once-off in nature. And that's as you'd expect, given these boosts are described as 'unusual'. ArcelorMittal had a rather significant contribution from unusual items relative to its profit to June 2025. All else being equal, this would likely have the effect of making the statutory profit a poor guide to underlying earnings power. That might leave you wondering what analysts are forecasting in terms of future profitability. Luckily, you can click here to see an interactive graph depicting future profitability, based on their estimates. Our Take On ArcelorMittal's Profit Performance As previously mentioned, ArcelorMittal's large boost from unusual items won't be there indefinitely, so its statutory earnings are probably a poor guide to its underlying profitability. For this reason, we think that ArcelorMittal's statutory profits may be a bad guide to its underlying earnings power, and might give investors an overly positive impression of the company. On the bright side, the company showed enough improvement to book a profit this year, after losing money last year. At the end of the day, it's essential to consider more than just the factors above, if you want to understand the company properly. Keep in mind, when it comes to analysing a stock it's worth noting the risks involved. In terms of investment risks, we've identified 1 warning sign with ArcelorMittal, and understanding it should be part of your investment process. Today we've zoomed in on a single data point to better understand the nature of ArcelorMittal's profit. But there is always more to discover if you are capable of focussing your mind on minutiae. For example, many people consider a high return on equity as an indication of favorable business economics, while others like to 'follow the money' and search out stocks that insiders are buying. While it might take a little research on your behalf, you may find this free collection of companies boasting high return on equity, or this list of stocks with significant insider holdings to be useful. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Yahoo
6 minutes ago
- Yahoo
Morgan Advanced Materials' (LON:MGAM) Dividend Will Be £0.054
Morgan Advanced Materials plc (LON:MGAM) has announced that it will pay a dividend of £0.054 per share on the 17th of November. This means the annual payment is 6.1% of the current stock price, which is above the average for the industry. AI is about to change healthcare. These 20 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10bn in marketcap - there is still time to get in early. Morgan Advanced Materials' Projected Earnings Seem Likely To Cover Future Distributions While it is great to have a strong dividend yield, we should also consider whether the payment is sustainable. Based on the last payment, the company wasn't making enough to cover what it was paying to shareholders. This situation certainly isn't ideal, and could place significant strain on the balance sheet if it continues. Over the next year, EPS is forecast to expand by 195.2%. Assuming the dividend continues along the course it has been charting recently, our estimates show the payout ratio being 42% which brings it into quite a comfortable range. View our latest analysis for Morgan Advanced Materials Dividend Volatility Although the company has a long dividend history, it has been cut at least once in the last 10 years. Since 2015, the annual payment back then was £0.109, compared to the most recent full-year payment of £0.122. This implies that the company grew its distributions at a yearly rate of about 1.1% over that duration. The dividend has seen some fluctuations in the past, so even though the dividend was raised this year, we should remember that it has been cut in the past. Morgan Advanced Materials Might Find It Hard To Grow Its Dividend Growing earnings per share could be a mitigating factor when considering the past fluctuations in the dividend. Morgan Advanced Materials has seen EPS rising for the last five years, at 28% per annum. EPS has been growing well, but Morgan Advanced Materials has been paying out a massive proportion of its earnings, which can make the dividend tough to maintain. Morgan Advanced Materials' Dividend Doesn't Look Sustainable Overall, it's nice to see a consistent dividend payment, but we think that longer term, the current level of payment might be unsustainable. Strong earnings growth means Morgan Advanced Materials has the potential to be a good dividend stock in the future, despite the current payments being at elevated levels. We don't think Morgan Advanced Materials is a great stock to add to your portfolio if income is your focus. Companies possessing a stable dividend policy will likely enjoy greater investor interest than those suffering from a more inconsistent approach. Meanwhile, despite the importance of dividend payments, they are not the only factors our readers should know when assessing a company. Case in point: We've spotted 4 warning signs for Morgan Advanced Materials (of which 1 is significant!) you should know about. Looking for more high-yielding dividend ideas? Try our collection of strong dividend payers. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data